FDA-approved
Hormones & metabolism
Pegvisomant
Evidence
FDA approved
Class
Growth hormone receptor antagonist
KEY TAKEAWAY
Pegvisomant is a modified growth hormone analog attached to polyethylene glycol. It is sold as Somavert. The FDA approved pegvisomant (Somavert) in 2003 for acromegaly.
Written by the Veylo editorial team · Updated
November 2026
What it is
Growth hormone receptor antagonist
Approved for
Acromegaly
Key fact
The FDA approved pegvisomant (Somavert) in 2003 for acromegaly.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Pegvisomant is a modified growth hormone analog attached to polyethylene glycol. It is sold as Somavert.
It binds the growth hormone receptor and blocks it, which lowers IGF-1 levels.
The FDA approved pegvisomant (Somavert) in 2003 for acromegaly.
Acromegaly.
Liver enzyme elevations can occur and are monitored. Injection-site reactions and flu-like symptoms are reported.
U.S. FDA prescribing information for Pegvisomant. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.